Ultragenyx Pharmaceutical Inc. (RARE) is scheduled to announce Q2 2021 earnings on Monday, 02 August 2021, after market close. Wallstreet estimates an EPS of $-1.31 and a revenue of $85.86 M in the upcoming results. Historically, Ultragenyx Pharmaceutical Inc. beated EPS estimates 41% of the times.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical, Inc. is a clinical-stage biotechnology company that is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. It intends to build therapies to address these clinically underserved diseases. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.